Literature DB >> 19053209

Peptide-based vaccines for cancer: realizing their potential.

Shreya Kanodia1, W Martin Kast.   

Abstract

Advances in the engineering of peptides, adjuvants and delivery systems have renewed the enthusiasm for peptide-based vaccination regimens in the setting of cancer, and there are a variety of clinical trials being conducted by pharmaceutical companies based on the use of peptides. The challenges to successful cancer immunotherapy are common to all immunotherapeutic strategies and not unique to peptide-based vaccination regimens. This review will describe the advances in the identification, design and delivery of peptides, the challenges to successful immunotherapy and will discuss potential options for the future.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19053209     DOI： 10.1586/14760584.7.10.1533

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  12 in total

1.  Carrageenan as an adjuvant to enhance peptide-based vaccine potency.

Authors:  Yu-Qian Zhang; Ya-Chea Tsai; Archana Monie; Chien-Fu Hung; T-C Wu
Journal:  Vaccine       Date:  2010-06-10       Impact factor: 3.641

2.  Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from proliferating cell nuclear antigen.

Authors:  Wei Xu; Hui-Zhong Li; Jun-Jie Liu; Zhen Guo; Bao-Fu Zhang; Fei-Fei Chen; Dong-Sheng Pei; Jun-Nian Zheng
Journal:  Tumour Biol       Date:  2010-08-16

Review 3.  Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.

Authors:  Amedeo Amedei; Elena Niccolai; Domenico Prisco
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Orchestration of CD4 T cell epitope preferences after multipeptide immunization.

Authors:  Jacqueline Tung; Andrea J Sant
Journal:  J Immunol       Date:  2013-06-14       Impact factor: 5.422

Review 5.  Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Yoshihiro Matsumoto; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

6.  Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.

Authors:  Mohamed S Arredouani; Bin Lu; Manoj Bhasin; Miriam Eljanne; Wen Yue; Juan-Miguel Mosquera; Glenn J Bubley; Vivian Li; Mark A Rubin; Towia A Libermann; Martin G Sanda
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

Review 7.  Enhancing immune responses to tumor-associated antigens.

Authors:  Jack P Higgins; Michael B Bernstein; James W Hodge
Journal:  Cancer Biol Ther       Date:  2009-08-01       Impact factor: 4.742

Review 8.  Current immunotherapeutic approaches in pancreatic cancer.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Shintaro Tsukinaga; Jimi Mitobe; Shunichi Odahara; Toyokazu Yukawa; Hiroshi Matsudaira; Keisuke Nagatsuma; Kan Uchiyama; Kenichi Satoh; Masaki Ito; Hideo Komita; Hiroshi Arakawa; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2011-09-14

Review 9.  What is recent in pancreatic cancer immunotherapy?

Authors:  Elena Niccolai; Domenico Prisco; Mario Milco D'Elios; Amedeo Amedei
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

Review 10.  Therapeutic vaccines and cancer: focus on DPX-0907.

Authors:  Mohan Karkada; Neil L Berinstein; Marc Mansour
Journal:  Biologics       Date:  2014-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.